ClinicalTrials.gg
CompletedNCT07213310Updated Feb 11, 2026

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

A Phase 1 interventional study of DWP16001 and DWC202511 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

Read the detailed description

A phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of DWC202511 or DWC202512 on the pharmacokinetics of DWP16001 and its metabolite in healthy adult subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 to 50 years at the time of screening.
  • 50.0 kg ≤ Body weight ≤ 90.0 kg and 18.5 ≤ (BMI) ≤ 29.9 kg/m² at the time of screening.
  • Written consent on voluntary decision of participation prior to the screening procedure after being fully informed of and completely understanding this study, etc.

Exclusion criteria

Exclusion Criteria:

  • Currect or history of hepatic, renal, kidney, nervous, immune, respiratory, gastrointestinal, endocrine, hematologic/oncologic conditions, cardiovascular, genitourinary, psychiatric, or sexual disorders.
  • History of gastrointestinal diseases (e.g., Crohn's disease, ulcers, gastritis, gastric spasms, gastroesophageal reflux disease) or surgeries (excluding simple appendectomy or hernia repair) that may affect the safety, pharmacokinetics, or pharmacodynamics of the product.
  • Current or history of gastrointestinal disorders or prior gastrointestinal surgery (except appendectomy or hernia repair) that may affect safety or PK/PD assessment of the investigational product.

Current or history of urinary tract infection or genital fungal infection.

  • Current or history of metabolic acidosis, such as diabetic ketoacidosis.
  • Genetic disorders including galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Single Arm: Sequential administration of DWC202511, DWC202512, and DWP16001

    Drug: DWP16001 · Drug: DWC202511 · Drug: DWC202512

Interventions

  • DWP16001 enavogliflozin (single oral dose) is administered in accordance with the study protocol.

  • DrugDWC202511

    Repeated oral administration of DWC202511 500 mg twice daily (BID), in accordance with the study protocol.

  • DrugDWC202512

    Repeated oral administration of DWC202512 once daily, in accordance with the study protocol

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 1 week

  2. AUClast

    Time frame: 1 week

Secondary outcomes

  1. AUCinf

    AUCinf of DWP16001 and DWP16001 metabolites

    Time frame: 1 week

  2. t1/2

    t1/2 of DWP16001 and DWP16001 metabolites

    Time frame: 1 week

  3. Tmax

    Tmax of DWP16001 and DWP16001 metabolites

    Time frame: 1 week

  4. CL/F

    CL/F of DWP16001

    Time frame: 1 week

  5. Vz/F

    Vz/F of DWP16001

    Time frame: 1 week

  6. metabolic ratio

    metabolic ratio of DWP16001 metabolites

    Time frame: 1 week

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Jong No Gu 03080, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jan 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Oct 8, 2025
StartActual
Nov 9, 2025
Primary completionActual
Jan 7, 2026
CompletionActual
Jan 7, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07213310
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Nov 9, 2025
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update
Feb 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion